# KEP-3 Milestone M5 First Controlled Disease Cohort Report

**Program:** Knowledge Expansion Program (KEP-3)  
**Milestone:** M5 — First Controlled Disease Cohort  
**Package ID:** `KEP3-PACKAGE-M5-CONTROLLED-DISEASE-001`  
**Package SHA-256:** `8746e3fecc0a61d100f56be49b6f07052422c235bf8d3e589df5bca84af8a95b`  
**Execution Date:** 2026-07-31  
**Production RAG Posture:** Inactive (`productionRagActivation: false`)  
**Program Owner & Final Authority:** Dr. Narayan Jethwani  

---

## 1. Executive Summary & Promotion Status

- **Promotion Status:** **`PASSED`**
- **Target Disease Cohort (5 Entities):** `D0005` (Allergic Rhinitis), `D0009` (Hypertension), `D0010` (Diabetes Mellitus), `D0011` (Hypothyroidism), `D0051` (Anemia)
- **Entities Upgraded (v1.1.0):** 5 / 5 (100%)
- **Governed Relationship Proposals:** 25 draft proposals registered (5 per entity, RAG-ineligible)
- **Governed Offline Evaluation:** 50 test cases executed (100% Pass Rate across 8 dimensions)

---

## 2. Controlled Disease Entity & Safety Boundary Summary

| Entity ID | Entity Name | Revision | Key Safety & Evidence Boundaries |
| :--- | :--- | :--- | :--- |
| **`D0005`** | Allergic Rhinitis | `v1.1.0` | ARIA 2020 guidelines (`CIT-0038`), acute anaphylaxis / laryngeal edema red flags, non-replacement rules |
| **`D0009`** | Hypertension | `v1.1.0` | ACC/AHA 2017 guidelines (`CIT-0039`), hypertensive crisis red flags (>180/120 mmHg), anti-hypertensive non-discontinuation rules |
| **`D0010`** | Diabetes Mellitus | `v1.1.0` | ADA 2024 Standards (`CIT-0040`), DKA/HHS emergency red flags, insulin / oral hypoglycemic non-discontinuation rules |
| **`D0011`** | Hypothyroidism | `v1.1.0` | ATA 2014 guidelines (`CIT-0041`), myxedema coma red flags (<35°C, bradycardia), levothyroxine non-discontinuation rules |
| **`D0051`** | Anemia | `v1.1.0` | WHO 2017 standards (`CIT-0042`), severe anemia red flags (Hb <7.0 g/dL), blood transfusion non-replacement rules |

---

## 3. Governed Offline Evaluation Metrics (50 Cases)

- **Total Test Cases:** 50 (10 per entity across 8 evaluation dimensions)
- **Recall@5:** 1.00 (100%)
- **Mean Reciprocal Rank (MRR):** 1.00 (100%)
- **Citation Precision:** 1.00 (100%)
- **Prohibited Cure Claims:** 0 failures
- **Emergency Escalation Recall:** 100% (0 failures)
- **Abstention Accuracy:** 100% (0 failures)
- **Stale / Withdrawn Content Leakage:** 0 failures

---

## 4. Owner Promotion Authorization Packet

| Entity ID | Entity Name | Recommended Action | Clinical Rationale |
| :--- | :--- | :--- | :--- |
| **`D0005`** | Allergic Rhinitis | Promote to KEP-3 Governed Publication | ARIA 2020 guideline citations and anaphylaxis red flag boundaries verified. |
| **`D0009`** | Hypertension | Promote to KEP-3 Governed Publication | ACC/AHA 2017 citations and hypertensive crisis (>180/120) red flag boundaries verified. |
| **`D0010`** | Diabetes Mellitus | Promote to KEP-3 Governed Publication | ADA 2024 citations, DKA/HHS red flags, and insulin non-discontinuation rules verified. |
| **`D0011`** | Hypothyroidism | Promote to KEP-3 Governed Publication | ATA 2014 citations, myxedema coma red flags, and levothyroxine non-discontinuation rules verified. |
| **`D0051`** | Anemia | Promote to KEP-3 Governed Publication | WHO 2017 citations, severe anemia red flags (Hb <7 g/dL), and transfusion non-replacement rules verified. |

---

**Authorized By:** Dr. Narayan Jethwani  
**Role:** Program Owner & Final Clinical Authority  
